We are live on ! Find out more
RDY icon

Dr. Reddy's Laboratories

242 hedge funds and large institutions have $1.62B invested in Dr. Reddy's Laboratories in 2025 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 107 increasing their positions, 61 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

75% more repeat investments, than reductions

Existing positions increased: 107 | Existing positions reduced: 61

20% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 30

11% more capital invested

Capital invested by funds: $1.46B → $1.62B (+$159M)

0.28% less ownership

Funds ownership: 13.16%12.88% (-0.28%)

0% less funds holding

Funds holding: 243242 (-1)

53% less call options, than puts

Call options by funds: $14K | Put options by funds: $30K

Holders
242
Holders Change
-1
Holders Change %
-0.41%
% of All Funds
3.19%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
36
Increased
107
Reduced
61
Closed
30
Calls
$14K
Puts
$30K
Net Calls
-$16K
Net Calls Change
-$247K
Name Holding Trade Value Shares
Change
Change in
Stake
Cerity Partners
51
Cerity Partners
New York
$2.61M -$263K -18,442 -10%
PP
52
Prudential plc
United Kingdom
$2.59M
OAC
53
OMERS Administration Corp
Ontario, Canada
$2.47M +$376K +26,300 +19%
ZIG
54
Zurich Insurance Group
Switzerland
$2.42M +$2.3M +160,870 New
CCM
55
Causeway Capital Management
California
$2.39M +$210K +14,700 +10%
Nordea Investment Management
56
Nordea Investment Management
Sweden
$2.21M +$106K +7,412 +5%
Legal & General Group
57
Legal & General Group
United Kingdom
$2.2M
CCIA
58
Campbell & Co Investment Adviser
Maryland
$2.19M +$2.08M +145,877 New
BP
59
Ballentine Partners
Massachusetts
$2.18M +$1M +70,110 +93%
LPL Financial
60
LPL Financial
California
$2.14M +$18.7K +1,308 +0.9%
SFA
61
Sequoia Financial Advisors
Ohio
$2.04M +$885K +61,964 +84%
AIM
62
Artemis Investment Management
United Kingdom
$2.03M -$2.09M -146,300 -52%
S
63
SignatureFD
Georgia
$2.02M +$315K +22,080 +20%
Prudential Financial
64
Prudential Financial
New Jersey
$1.92M -$577K -40,400 -24%
IQI
65
Integrated Quantitative Investments
Washington
$1.91M +$1.82M +127,400 New
SEI Investments
66
SEI Investments
Pennsylvania
$1.87M +$378K +26,500 +27%
SGI
67
Summit Global Investments
Utah
$1.86M -$24K -1,683 -1%
Corient Private Wealth
68
Corient Private Wealth
Florida
$1.83M +$63K +4,410 +4%
VEA
69
Virtus ETF Advisers
New York
$1.79M
GT
70
Greenleaf Trust
Michigan
$1.78M +$14.7K +1,028 +0.9%
BCI
71
Brinker Capital Investments
Pennsylvania
$1.76M +$466K +32,664 +39%
Pathstone Holdings
72
Pathstone Holdings
New Jersey
$1.67M +$284K +19,889 +22%
Fidelity Investments
73
Fidelity Investments
Massachusetts
$1.61M +$134K +9,356 +10%
Citadel Advisors
74
Citadel Advisors
Florida
$1.51M -$848K -59,361 -37%
Amundi
75
Amundi
France
$1.46M

RDY Hedge Fund Activity: Q2 2025 in Review

242 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q2 2025, worth a combined $1.62B — up 11% from $1.46B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new RDY positions and 30 closed out — a net gain of 6 holders — while 107 added to existing stakes and 61 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $51.7M. The largest seller was Morgan Stanley, cutting an estimated $55.4M.

  • 242 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q2 2025, down from 243 in Q1 2025.
  • Funds reported $1.62B of Dr. Reddy's Laboratories stock for Q2 2025, up 11% quarter-over-quarter.
  • 36 funds opened new Dr. Reddy's Laboratories positions in Q2 2025 and 30 closed out, a net change of +6 holders.
  • The largest Dr. Reddy's Laboratories buyer in Q2 2025 was JP Morgan Chase, an estimated $51.7M added.
  • The largest Dr. Reddy's Laboratories seller in Q2 2025 was Morgan Stanley, an estimated $55.4M sold.

Based on aggregated 13F filings for Q2 2025.